


5. Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma in patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355-1361.


8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma, V.3.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed June 20, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

